Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Ligand Reports Second Quarter 2018 Financial Results
Ligand to Report Second Quarter 2018 Results on August 6th
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
Ligand Prices Offering of $650 Million of Convertible Senior Notes
Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
Ligand to Participate in Upcoming Investor Conferences
Ligand Reports First Quarter 2018 Financial Results
Ligand to Report First Quarter 2018 Results on May 8th
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
